IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!!

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Flea who wrote (13)	9/22/1997 9:12:00 PM
From: the Chief	of 94

Contract Awarded for Approval Process of New Cancer Drug IGT PHARMA release 22 September 1997 IGT is pleased to announce the signing of a clinical development contract for its new drug Anhydrovinblastine AVLB. Effective immediately L.A.B. Biosyn Corp. will be assisting IGT in the regulatory strategy development and pre-clinical data management leading to the submission of an Investigational New Drug Application (IND) for the U.S. FDA and the Canadian HPB. Upon acceptance of the IND by the regulatory authorities, human clinical trials using AVLB will commence at selected canacer hospitals in North America. The Planned indication of use will be in the treatment of one of the worlds most lethal canacers, non-small cell lung cancer, a condition most commonly associated with smoking. L.A.B. Biosysn, a subsidiary of L.A.B. International is a contract research organization (CRO) based in Montreal which provides services in the fields of formulation, regulatory affairs, clinical research, and program management to the pharmaceutical industry in the Americas, Europe and Asia. Eli Farah, President of L.A.B. Biosyn remarked: We are pleased to have formed this association with IGT Pharma. I believe that this agreement illustrates the favourable evolution of companies such as IGT to an international presence which, in today's pharmaceutical industry, is a pre-requisite for success. We look forward to a long standing relationship with IGT. IGT PHarma is a vancouver based bio-pharmaceutical company focused on the innovation and enhancement of cancer therapies using synthetic chemistry. IGT's business plan involves the utilization of novel low cost production methods for both new and existing anti-cancer drugs. On behalf of the board of directors IGT Pharma INC. Bruce Schmidt, President

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next